EU progress on human tissue products regulation stalls again
This article was originally published in Clinica
The European Commission is delaying again publication of the first draft of the EU's Human Tissue Engineered Products (HTEP) Regulation. The results of further investigations into how research in hospitals into HTEPs would be affected by the current version of the proposed document has persuaded the Commission to carry out further changes.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.